Introduction
It is now generally recognized that a primary tuberculous infection evokes a definite degree of acquired resistance to reinfection. This primary infection, though usually innocuous to the European, may produce progressive disease. For the last seventy years research has been directed towards finding a vaccine that will produce an avirulent primary infection and evoke acquired resistance in safety; from this has emerged tke B.C.G. vaccine and, more recently, the Vole vaccine.
The history of B.C.G. up to 1948 has been dealt with in detail elsewhere (Irvine, 1949) ; this article is primarily concerned with advances which have occurred since then and with its recent introduction into this country.
Safety
For the first time in the last twenty years some investigators have reported that they have been able to produce progressive disease in animals with B.C.G. Hauduroy and Rosset (I95I) have produced progressive disease and death by inoculating B.C.G. into hamsters; Vorwald et al. (1950) have had similar results in silicotic guinea-pigs and Dubos (1949) Though it is still too early to assess the exact degree of its efficacy, the preliminary reports are very encouraging.
Weight for weight, vole vaccine is about ten times as strong as B.C.G., judged by the reactions produced in man. Conversion rates of Ioo per cent. are usual after multiple-puncture through 2 mg. ml. vole vaccine, while for comparable results 20 mg. ml. B.C.G. is required. The optimum intracutaneous dose is being worked out at the moment.
The advantage of the vole vaccine is that it can be maintained at a steady degree of virulence. Should any variation in the strain be observed after repeated subculture, the normal virulence can be restored at once by passage through a vole. 'There is no animal through which a similar passage can be made with B.C.G. and it has had to be maintained on artificial media for 44 years; the only way of correcting variations in its virulence is to alter the medium in which it is grown. The disadvantage of the vole vaccine is that it grows poorly on any artificial medium and the production of sufficient vaccine for large-scale vaccination is at the moment difficult.
The Future
Up to the present the Ministry has restricted the use of B.C.G. to medical students, nurses and contacts. In some quarters pressure is already being brought to bear for an extension of these limits; in particular the vaccination of all schoolleavers is being advocated. From this he has now extracted an antibiotic substance (Protaptin) which is enormously potent against the tubercle bacillus and has been highly successful in the treatment of infected guinea pigs. Clinical trials were about to begin last July. Not only the substance, but the method has tremendous possibilities.
As to man's pertinacity and his powers of application, we need only mention the story of streptomycin, which was the only one of more than a thousand similar compounds investigated in great detail by Waksmann which has proved useful. For these and many other reasons we take the view that advance continues; that ingenuity is still with us as it always has been, like the golden thread of romance showing itself here and there, sometimes in the least expected quarters. We believe that, at the present moment, no line is likely to be more productive than that of the prevention and eradication of tuberculosis. We pray that we in our lifetime may hold similar views on the subject of cancer.
